Japan, South Korea, and the United Kingdom (notably Moorfields Eye Hospital and other major research centres) are leading in human retinal cell-therapy trials. Switzerland offers private treatment at premium cost (€12,000–20,000). The United States has active research programmes but limited commercial availability.
Cell therapy for macular degeneration remains expensive and largely experimental. Treatment costs range from €6,000 to €15,000+ per eye, reflecting iPSC derivation, long-term cell expansion, quality-control testing, and the technical complexity of subretinal or intravitreal injection. Baseline and follow-up imaging (optical coherence tomography [OCT], visual field testing, electroretinography) adds €2,000–4,000. The condition typically affects both eyes, so bilateral treatment approaches €15,000–30,000.
Съм ли кандидат? → · Macular Degeneration & Vision: full overview → · Цена Макулна дегенерация и зрение → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка